MRK vs MRNA
By Alex · Tickerpine
Merck & Co., Inc. vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | MRNA |
|---|---|---|
| Price | $128.66 | $67.27 |
| Market cap | $317.77B | $26.69B |
| P/E ratio | 36.2 | — |
| ROE | 18.94% | -36.56% |
| Profit margin | 13.59% | -143.55% |
| Revenue growth | 4.90% | 260.20% |
| Dividend yield | 2.64% | — |
| Beta | 0.22 | 1.03 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs MRNA in plain English
- MRK is the bigger company — about 11.9× the market cap of MRNA.
- MRK earns a higher return on equity (19% vs -37%).
- MRNA is growing revenue faster (260% vs 5%).
- MRK pays a dividend (2.64%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.